NCT04408638进行中（未招募）3 期
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 270
- 试验地点
- 94
- 主要终点
- Overall survival (OS), defined as the time from randomization to date of death from any cause
研究概览
简要总结
This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (Glofit-GemOx) compared with rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx) in patients with R/R DLBCL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diffuse large B-cell lymphoma (DLBCL), not otherwise specified
- •Relapsed/refractory (R/R) disease, defined as follows: Relapsed = disease that has recurred ≥6 months after completion of the last line of therapy; Refractory = disease that either progressed during the last line of therapy or progressed within 6 months (<6 months) of the last line of prior therapy
- •At least one (≥1) line of prior systemic therapy
- •Participants who have failed only one prior line of therapy must not be a candidate for high-dose chemotherapy followed by autologous stem cell transplant, as defined by the study protocol
- •Confirmed availability of tumor tissue, unless unobtainable per investigator assessment. Freshly collected biopsy is preferred. Archival tissue is acceptable
- •At least one bi-dimensionally measurable (≥1.5 cm) nodal lesion, or one bi-dimensionally measurable (≥1 cm) extranodal lesion, as measured on computed tomography (CT) scan
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
- •Adequate hematologic function (unless attributable to the underlying disease, as established by extensive bone marrow involvement or associated with hypersplenism secondary to the involvement of the spleen by DLBCL per the investigator), as defined by the study protocol
- •Negative SARS-CoV-2 antigen or PCR test within 7 days prior to enrollment
- •Adequate renal function, defined as an estimated creatinine clearance ≥30 mL/min
排除标准
- •Patient has failed only one prior line of therapy and is a candidate for stem cell transplantation
- •History of transformation of indolent disease to DLBCL
- •High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, and high-grade B-cell lymphoma not otherwise specified, as defined by 2016 WHO guidelines
- •Primary mediastinal B-cell lymphoma
- •History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products
- •Contraindication to obinutuzumab, rituximab, gemcitabine or oxaliplatin, or tocilizumab
- •Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3
- •Peripheral neuropathy assessed to be Grade >1 according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 at enrollment
- •Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to first study treatment
- •Treatment with monoclonal antibodies for the purposes of treating cancer within 4 weeks prior to first study treatment
- •Primary or secondary central nervous system (CNS) lymphoma at the time of recruitment or history of CNS lymphoma
- •Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
- •Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection (as evaluated by the investigator) within 4 weeks prior to the first study treatment
- •Positive SARS-CoV-2 infection within 30 days prior to the first study treatment, including asymptomatic SARS-CoV-2 infection
- •Documented SARS-CoV-2 infection within 6 months of first study treatment
- •Suspected or latent tuberculosis
- •Positive for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
- •Known or suspected chronic active Epstein-Barr viral infection
- •Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
- •Known history of progressive multifocal leukoencephalopathy
- •Adverse events from prior anti-cancer therapy not resolved to Grade 1 or better (with the exception of alopecia and anorexia)
- •Administration of a live, attenuated vaccine within 4 weeks before first study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study
- •Prior solid organ transplantation
- •Prior allogeneic stem cell transplant
- •Active autoimmune disease requiring treatment
- •Prior treatment with systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents), within 4 weeks prior to first dose of study treatment
- •Corticosteroid therapy within 2 weeks prior to first dose of study treatment (exceptions defined by study protocol)
- •Recent major surgery (within 4 weeks before the first study treatment) other than for diagnosis
- •Clinically significant history of cirrhotic liver disease
研究组 & 干预措施
Glofit-GemOx
Experimental
Participants will receive up to 8 cycles of glofitamab (Glofit) in combination with gemcitabine and oxaliplatin (GemOx), followed by up to 4 cycles of glofitamab monotherapy. A single dose of obinutuzumab will be administered 7 days prior to the first dose of glofitamab. Treatment is administered in 21-day cycles.
干预措施: Obinutuzumab (Drug)
Glofit-GemOx
Experimental
Participants will receive up to 8 cycles of glofitamab (Glofit) in combination with gemcitabine and oxaliplatin (GemOx), followed by up to 4 cycles of glofitamab monotherapy. A single dose of obinutuzumab will be administered 7 days prior to the first dose of glofitamab. Treatment is administered in 21-day cycles.
干预措施: Gemcitabine (Drug)
Glofit-GemOx
Experimental
Participants will receive up to 8 cycles of glofitamab (Glofit) in combination with gemcitabine and oxaliplatin (GemOx), followed by up to 4 cycles of glofitamab monotherapy. A single dose of obinutuzumab will be administered 7 days prior to the first dose of glofitamab. Treatment is administered in 21-day cycles.
干预措施: Glofitamab (Drug)
Glofit-GemOx
Experimental
Participants will receive up to 8 cycles of glofitamab (Glofit) in combination with gemcitabine and oxaliplatin (GemOx), followed by up to 4 cycles of glofitamab monotherapy. A single dose of obinutuzumab will be administered 7 days prior to the first dose of glofitamab. Treatment is administered in 21-day cycles.
干预措施: Tocilizumab (Drug)
Glofit-GemOx
Experimental
Participants will receive up to 8 cycles of glofitamab (Glofit) in combination with gemcitabine and oxaliplatin (GemOx), followed by up to 4 cycles of glofitamab monotherapy. A single dose of obinutuzumab will be administered 7 days prior to the first dose of glofitamab. Treatment is administered in 21-day cycles.
干预措施: Oxaliplatin (Drug)
R-GemOx
Experimental
Participants will receive rituxumab (R) in combination with gemcitabine and oxaliplatin (GemOx) for up to 8 cycles. Treatment is administered in 21-day cycles.
干预措施: Gemcitabine (Drug)
R-GemOx
Experimental
Participants will receive rituxumab (R) in combination with gemcitabine and oxaliplatin (GemOx) for up to 8 cycles. Treatment is administered in 21-day cycles.
干预措施: Rituxumab (Drug)
R-GemOx
Experimental
Participants will receive rituxumab (R) in combination with gemcitabine and oxaliplatin (GemOx) for up to 8 cycles. Treatment is administered in 21-day cycles.
干预措施: Oxaliplatin (Drug)
结局指标
主要结局
Overall survival (OS), defined as the time from randomization to date of death from any cause
时间窗: Up to 5 years
次要结局
- Progression-free survival (PFS), defined as the time from randomization to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined by the Independent Review Committee (IRC)(Up to 5 years)
- PFS, defined as the time from randomization to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined by the investigator(Up to 5 years)
- ORR, defined as the proportion of patients whose best overall response is a partial response (PR) or a CR during the study, as determined by the investigator(Up to 5 years)
- Complete response (CR) rate, defined as the proportion of patients whose best overall response is a CR on positron emission tomography/computed tomography (PET/CT) during the study, as determined by the IRC(Up to 5 years)
- Duration of objective response (DOR), defined as the time from the first occurrence of a documented objective response (CR or PR) to disease progression, or death from any cause, whichever occurs first(Up to 5 years)
- Time to deterioration in lymphoma symptoms, as measured by the Functional Assessment of Cancer Therapy-Lymphoma subscale (FACT-Lym LymS)(Up to 5 years)
- CR rate, defined as the proportion of patients whose best overall response is a CR on positron emission tomography/computed tomography (PET/CT) during the study, as determined by the investigator(Up to 5 years)
- Objective response rate (ORR), defined as the proportion of patients whose best overall response is a partial response (PR) or a CR during the study, as determined by the IRC(Up to 5 years)
- Duration of CR, defined as the time from the first occurrence of a documented CR to disease progression, or death from any cause, whichever occurs first(Up to 5 years)
- Time to deterioration in physical functioning and fatigue, as measured by the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire (EORTC QLQ-C30)(Up to 5 years)
- Percentage of Participants with Adverse Events(Up to 5 years)
- Tolerability, as assessed by dose interruptions, dose reductions, and dose intensity, and study treatment discontinuation because of adverse events(Up to 5 years)
研究者
研究点 (94)
Loading locations...
相似试验
进行中（未招募）
3 期
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell LymphomaNCT06047080Hoffmann-La Roche1,130
招募中
1 期
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaLymphomaNCT06624085Hoffmann-La Roche50
已完成
1 期
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCLNon-Hodgkin LymphomaB-Cell LymphomaNCT03467373Hoffmann-La Roche111
招募中
3 期
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaLymphomaNCT06084936Hoffmann-La Roche182
已完成
1 期
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell LymphomaB-cell LymphomaNCT04313608Hoffmann-La Roche23
相关资讯
Subsidised Access to Columvi (Glofitamab) Now Available for Relapsed/Refractory DLBCL Patients in Singapore- Columvi (glofitamab) will be added to Singapore's Cancer Drug List and Medication Assistance Fund on 1 September 2026 for eligible relapsed or refractory DLBCL patients.
- Eligible Singapore Citizens and Permanent Residents will receive subsidies of up to 75% and 20%, respectively, at public healthcare institutions.
- In the phase III STARGLO study, glofitamab plus GemOx doubled overall survival versus rituximab plus GemOx (25.5 vs 12.9 months).
- The off-the-shelf CD20xCD3 bispecific antibody offers immediate treatment access for patients ineligible for ASCT or CAR-T cell therapy.15 days agoFDA Accepts sBLA for Glofitamab Plus Chemotherapy in Relapsed/Refractory DLBCL- The FDA has accepted Roche's sBLA for glofitamab combined with gemcitabine and oxaliplatin (GemOx) for relapsed/refractory DLBCL patients ineligible for autologous stem cell transplant.
- The sBLA is based on the phase 3 STARGLO trial, which demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to rituximab plus GemOx.
- The FDA is expected to make a decision on the approval of glofitamab in combination with GemOx by July 20, 2025, offering a potential new treatment option.
- The safety profile of glofitamab plus GemOx was consistent with the known safety profiles of the individual agents, with cytokine release syndrome being a common adverse event.last year